{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T17:52:17Z","timestamp":1794592337819,"version":"4.9.1"},"reference-count":36,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T00:00:00Z","timestamp":1662681600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Pharmacosmos A\/S","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Gut"],"accepted":{"date-parts":[[2022,8,20]]},"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Intravenous iron\u2014a common treatment for anaemia and iron deficiency due to inflammatory bowel disease (IBD)\u2014can cause hypophosphataemia. This trial compared the incidence of hypophosphataemia after treatment with ferric carboxymaltose (FCM) or ferric derisomaltose (FDI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>This randomised, double-blind, clinical trial was conducted at 20 outpatient hospital clinics in Europe (Austria, Denmark, Germany, Sweden, UK). Adults with IBD and iron deficiency anaemia (IDA) were randomised 1:1 to receive FCM or FDI at baseline and at Day 35 using identical haemoglobin- and weight-based dosing regimens. The primary outcome was the incidence of hypophosphataemia (serum phosphate &lt;2.0 mg\/dL) at any time from baseline to Day 35 in the safety analysis set (all patients who received \u22651 dose of study drug). Markers of mineral and bone homeostasis, and patient-reported fatigue scores, were measured.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 156 patients were screened; 97 (49 FDI, 48 FCM) were included and treated. Incident hypophosphataemia occurred in 8.3% (4\/48) FDI-treated patients and in 51.0% (25\/49) FCM-treated patients (adjusted risk difference: \u221242.8% (95% CI \u201357.1% to \u201324.6%) p&lt;0.0001). Both iron formulations corrected IDA. Patient-reported fatigue scores improved in both groups, but more slowly and to a lesser extent with FCM than FDI; slower improvement in fatigue was associated with greater decrease in phosphate concentration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Despite comparably effective treatment of IDA, FCM caused a significantly higher rate of hypophosphataemia than FDI. Further studies are needed to address the longer-term clinical consequences of hypophosphataemia and to investigate mechanisms underpinning the differential effects of FCM and FDI on patient-reported fatigue.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/gutjnl-2022-327897","type":"journal-article","created":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T13:30:37Z","timestamp":1662730237000},"page":"644-653","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":103,"title":["Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial"],"prefix":"10.1136","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1794-422X","authenticated-orcid":false,"given":"Heinz","family":"Zoller","sequence":"first","affiliation":[{"name":"Department of Medicine I and Christian Doppler Laboratory on Iron and Phosphate Biology, Medical University of Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myles","family":"Wolf","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, and Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Blumenstein","sequence":"additional","affiliation":[{"name":"Medical Clinic I, Department of Gastroenterology, Hepatology, and Clinical Nutrition, University Clinic Frankfurt, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Primas","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Lindgren","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Sk\u00e5ne University Hospital Malm\u00f6, Lund University, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars L","family":"Thomsen","sequence":"additional","affiliation":[{"name":"Department of Clinical and Non-Clinical Research, Pharmacosmos A\/S, Holb\u00e6k, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Reinisch","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tariq","family":"Iqbal","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Queen Elizabeth Hospital Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,9,9]]},"reference":[{"key":"2025112108152525000_72.4.644.1","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1097\/01.MIB.0000442728.74340.fd","article-title":"Prevalence of anemia in inflammatory bowel diseases in European countries: a systematic review and individual patient data meta-analysis","volume":"20","author":"Filmann","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"2025112108152525000_72.4.644.2","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20285"},{"key":"2025112108152525000_72.4.644.3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2008.01846.x"},{"key":"2025112108152525000_72.4.644.4","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2017-000155"},{"key":"2025112108152525000_72.4.644.5","doi-asserted-by":"publisher","DOI":"10.1016\/50140-6736(20)32594-0"},{"key":"2025112108152525000_72.4.644.6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2005.00058.x"},{"key":"2025112108152525000_72.4.644.7","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jju009"},{"key":"2025112108152525000_72.4.644.8","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/apt.15386","article-title":"Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside","volume":"50","author":"Detlie","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"2025112108152525000_72.4.644.9","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/ajh.25564","article-title":"A prospective, multi-center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia; the FERWON-IDA trial","volume":"94","author":"Auerbach","year":"2019","journal-title":"Am J Hematol"},{"key":"2025112108152525000_72.4.644.10","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.06.005"},{"key":"2025112108152525000_72.4.644.11","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.1923"},{"key":"2025112108152525000_72.4.644.12","doi-asserted-by":"publisher","DOI":"10.1258\/acb.2008.008151"},{"key":"2025112108152525000_72.4.644.13","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1080\/14740338.2021.1912010","article-title":"Newer formulations of intravenous iron: a review of their chemistry and key safety aspects \u2013 hypersensitivity, hypophosphatemia, and cardiovascular safety","volume":"20","author":"Blumenstein","year":"2021","journal-title":"Expert Opin Drug Saf"},{"key":"2025112108152525000_72.4.644.14","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1111\/bcp.14643","article-title":"Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside \u2013 a systematic review and meta-analysis","volume":"87","author":"Schaefer","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"2025112108152525000_72.4.644.15","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/jama.2019.22450","article-title":"Effects of iron isomaltoside vs ferric carboxymaltose on hypophosphatemia in iron-deficiency anemia: two randomized clinical trials","volume":"323","author":"Wolf","year":"2020","journal-title":"JAMA"},{"key":"2025112108152525000_72.4.644.16","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.124486","article-title":"Randomized trial of intravenous iron-induced hypophosphatemia","volume":"3","author":"Wolf","year":"2018","journal-title":"JCI Insight"},{"key":"2025112108152525000_72.4.644.17","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.44","article-title":"Tumour-induced osteomalacia","volume":"3","author":"Minisola","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"2025112108152525000_72.4.644.18","doi-asserted-by":"publisher","DOI":"10.1097\/MNH.0000000000000329"},{"key":"2025112108152525000_72.4.644.19","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.2002.32799"},{"key":"2025112108152525000_72.4.644.20","unstructured":"Monofer 100 mg\/ml solution for injection\/infusion . Summary of product characteristics (SmPC). 26. Pharmacosmos UK Ltd, 26 May 2020."},{"key":"2025112108152525000_72.4.644.21","unstructured":"Ferinject (ferric carboxymaltose) . Summary of product characteristics (SmPC). Vifor Pharma UK Ltd, November 2021."},{"key":"2025112108152525000_72.4.644.22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04871.x"},{"key":"2025112108152525000_72.4.644.23","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2147\/TCRM.S243462","article-title":"Hypophosphatemia associated with intravenous iron therapies for iron deficiency anemia: a systematic literature review","volume":"16","author":"Glaspy","year":"2020","journal-title":"Ther Clin Risk Manag"},{"key":"2025112108152525000_72.4.644.24","doi-asserted-by":"publisher","DOI":"10.1136\/flgastro-2020-101406"},{"key":"2025112108152525000_72.4.644.25","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/apt.14231","article-title":"Letter: inconsistency in reporting of hypophosphatemia after intravenous iron","volume":"46","author":"Schaefer","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"2025112108152525000_72.4.644.26","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2021.116202","article-title":"Hypophosphatemia after intravenous iron therapy: comprehensive review of clinical findings and recommendations for management","volume":"154","author":"Schaefer","year":"2022","journal-title":"Bone"},{"key":"2025112108152525000_72.4.644.27","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2020.100862","article-title":"Intravenous iron supplementation therapy","volume":"75","author":"Schaefer","year":"2020","journal-title":"Mol Aspects Med"},{"key":"2025112108152525000_72.4.644.28","unstructured":"European Medicine\u2019s Agency . Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s). Available: https:\/\/www.ema.europa.eu\/en\/documents\/psusa\/iron-parenteral-preparations-except-iron-dextran-cmdh-scientific-conclusions-grounds-variation\/00010236\/202001_en.pdf [Accessed 22 Feb 2022]."},{"key":"2025112108152525000_72.4.644.29","unstructured":"Government UK . Ferric carboxymaltose (Ferinject\u25bc): risk of symptomatic hypophosphataemia leading to osteomalacia and fractures. Available: https:\/\/www.gov.uk\/drug-safety-update\/ferric-carboxymaltose-ferinject-risk-of-symptomatic-hypophosphataemia-leading-to-osteomalacia-and-fractures [Accessed 22 Feb 2022]."},{"key":"2025112108152525000_72.4.644.30","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2013.335"},{"key":"2025112108152525000_72.4.644.31","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu385"},{"key":"2025112108152525000_72.4.644.32","doi-asserted-by":"publisher","DOI":"10.1186\/s12884-018-1817-y"},{"key":"2025112108152525000_72.4.644.33","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830460422"},{"key":"2025112108152525000_72.4.644.34","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702407"},{"key":"2025112108152525000_72.4.644.35","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000275286.03283.18"},{"key":"2025112108152525000_72.4.644.36","doi-asserted-by":"crossref","DOI":"10.3390\/nu11051019","article-title":"The role of vitamin D in inflammatory bowel disease: mechanism to management","volume":"11","author":"Fletcher","year":"2019","journal-title":"Nutrients"}],"container-title":["Gut"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/gutjnl-2022-327897","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T16:15:35Z","timestamp":1763741735000},"score":1,"resource":{"primary":{"URL":"https:\/\/gut.bmj.com\/lookup\/doi\/10.1136\/gutjnl-2022-327897"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,9]]},"references-count":36,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,3,7]]},"published-print":{"date-parts":[[2023,4]]}},"alternative-id":["10.1136\/gutjnl-2022-327897"],"URL":"https:\/\/doi.org\/10.1136\/gutjnl-2022-327897","relation":{},"ISSN":["0017-5749","1468-3288"],"issn-type":[{"value":"0017-5749","type":"print"},{"value":"1468-3288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,9]]}}}